{"id":"W2110534364","doi":"10.1056/nejmoa1014618","title":"Abiraterone and Increased Survival in Metastatic Prostate Cancer","year":2011,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4394,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; Université de Montréal; BC Cancer Agency","funders":"National Cancer Institute","keywords":"Abiraterone acetate; Medicine; Prednisone; Prostate cancer; Hazard ratio; Internal medicine; Urology; Clinical endpoint; Placebo; Antiandrogen; Interim analysis; Adverse effect; Androgen deprivation therapy; Oncology; Randomized controlled trial; Cancer; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}